Matisse Capital’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,250
| Closed | -$789K | – | 167 |
|
|
2025
Q4 | $789K | Hold |
2,250
| – | – | 0.35% | 74 |
|
|
2025
Q3 | $727K | Sell |
2,250
-100
| -4% | -$31.1K | 0.33% | 81 |
|
|
2025
Q2 | $914K | Hold |
2,350
| – | – | 0.43% | 76 |
|
|
2025
Q1 | $1.02M | Hold |
2,350
| – | – | 0.54% | 61 |
|
|
2024
Q4 | $867K | Sell |
2,350
-200
| -8% | -$83.7K | 0.44% | 74 |
|
|
2024
Q3 | $1.33M | Hold |
2,550
| – | – | 0.64% | 50 |
|
|
2024
Q2 | $1.38M | Sell |
2,550
-137
| -5% | -$72.4K | 0.68% | 50 |
|
|
2024
Q1 | $1.39M | Sell |
2,687
-200
| -7% | -$99.5K | 0.67% | 46 |
|
|
2023
Q4 | $1.36M | Buy |
2,887
+1,400
| +94% | +$647K | 0.73% | 39 |
|
|
2023
Q3 | $647K | Sell |
1,487
-2,000
| -57% | -$907K | 0.46% | 84 |
|
|
2023
Q2 | $1.55M | Hold |
3,487
| – | – | 0.96% | 19 |
|
|
2023
Q1 | $1.6M | Hold |
3,487
| – | – | 1.03% | 16 |
|
|
2022
Q4 | $1.79M | Buy |
+3,487
| New | +$1.77M | 1.59% | 10 |
|
|
2022
Q3 | – | Sell |
-3,622
| Closed | -$1.75M | – | 96 |
|
|
2022
Q2 | $1.75M | Hold |
3,622
| – | – | 1.66% | 13 |
|
|
2022
Q1 | $1.78M | Buy |
3,622
+350
| +11% | +$160K | 1.64% | 16 |
|
|
2021
Q4 | $1.52M | Sell |
3,272
-1,000
| -23% | -$421K | 1.05% | 24 |
|
|
2021
Q3 | $1.59M | Hold |
4,272
| – | – | 0.59% | 45 |
|
|
2021
Q2 | $1.63M | Buy |
4,272
+2,000
| +88% | +$764K | 0.52% | 53 |
|
|
2021
Q1 | $815K | Hold |
2,272
| – | – | 0.23% | 81 |
|
|
2020
Q4 | $729K | Hold |
2,272
| – | – | 0.23% | 87 |
|
|
2020
Q3 | $610K | Hold |
2,272
| – | – | 0.24% | 73 |
|
|
2020
Q2 | $597K | Hold |
2,272
| – | – | 0.2% | 90 |
|
|
2020
Q1 | $516K | Buy |
2,272
+825
| +57% | +$225K | 0.2% | 99 |
|
|
2019
Q4 | $437K | Hold |
1,447
| – | – | 0.31% | 66 |
|
|
2019
Q3 | $347K | Hold |
1,447
| – | – | 0.43% | 59 |
|
|
2019
Q2 | $408K | Hold |
1,447
| – | – | 0.52% | 47 |
|
|
2019
Q1 | $415K | Sell |
1,447
-87
| -6% | -$25.2K | 0.5% | 52 |
|
|
2018
Q4 | $403K | Hold |
1,534
| – | – | 0.51% | 48 |
|
|
2018
Q3 | $420K | Buy |
1,534
+85
| +6% | +$22.1K | 0.38% | 68 |
|
|
2018
Q2 | $345K | Hold |
1,449
| – | – | 0.27% | 80 |
|
|
2018
Q1 | $318K | Hold |
1,449
| – | – | 0.19% | 91 |
|
|
2017
Q4 | $326K | Hold |
1,449
| – | – | 0.15% | 100 |
|
|
2017
Q3 | $275K | Hold |
1,449
| – | – | 0.13% | 97 |
|
|
2017
Q2 | $273K | Buy |
+1,449
| New | +$260K | 0.14% | 91 |
|
Other funds holding ELV
VCM
VPM
Matisse Capital's ELV Position: Q1 2026 in Review
Matisse Capital sold out of Elevance Health (ELV) in Q1 2026, closing a stake of 2,250 shares — an estimated $789K sold.
Matisse Capital first reported a position in ELV in Q2 2017 and held it in 34 quarters. The position peaked at $1.79M in Q4 2022. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- Matisse Capital reported no remaining Elevance Health position as of Q1 2026 after selling out during the quarter.
- Matisse Capital sold 2,250 Elevance Health shares in Q1 2026, an estimated $789K.
- Matisse Capital first reported a position in Elevance Health in Q2 2017 and held it in 34 quarters.
- Matisse Capital's Elevance Health position peaked at $1.79M in Q4 2022.
- 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on Matisse Capital's 13F filing for Q1 2026, filed 8 May 2026.